The lacrimal gland is the tear-making gland. You have one above each eye, tucked into the outer (temporal) corner of the upper eyelid. It sits in a shallow bone pocket called the lacrimal fossa. Its job is to make the watery part of your tears, which keep the eye clear, smooth, and comfortable.

A tumor is an abnormal growth of cells that forms a lump. In the lacrimal gland, tumors can be:

• Benign (non-cancerous): they grow slowly and don’t invade nearby tissues or spread to other parts of the body.

• Malignant (cancerous): they can invade surrounding structures, damage nerves and bone, and may spread (metastasize).

A lacrimal gland mass can also be an inflammatory condition (not a true tumor) that looks and feels like a tumor. Doctors must carefully sort out which is which, because treatment is very different.

Typical clues:

• Slow, painless swelling over months to years favors a benign tumor.

• Rapid growth, pain, bone changes, or numbness favor a malignant tumor.

• Soreness, redness, and tenderness can point to inflammation rather than a tumor.

---

Types of lacrimal gland tumors

1. Pleomorphic adenoma (benign mixed tumor)
   The most common benign epithelial tumor. “Pleomorphic” means it has mixed cell types. It usually causes a slow, painless, firm swelling in the outer upper eyelid. It must be removed in one piece with its capsule to prevent recurrence.

2. Oncocytoma (benign)
   A rare benign tumor made of oncocytes (cells packed with mitochondria). Usually slow-growing and painless.

3. Monomorphic (basal cell or canalicular) adenoma (benign)
   Benign gland tumors with a more uniform look under the microscope. Typically slow and non-tender.

4. Adenoid cystic carcinoma (ACC) (malignant)
   The most feared malignant epithelial tumor here. It often causes pain (because it can grow along nerves), can erode bone, and may spread locally or distantly. Needs urgent, specialized care.

5. Carcinoma ex pleomorphic adenoma (malignant)
   A long-standing benign pleomorphic adenoma that has changed into a cancer. Warning signs include new rapid growth or pain in a mass that used to be quiet.

6. Mucoepidermoid carcinoma (malignant)
   A cancer with mixed cell types (mucus-making and skin-like cells). Behavior ranges from low to high grade.

7. Acinic cell carcinoma (malignant)
   A cancer that looks like acinar (secretory) cells of salivary/lacrimal tissue. Usually slower than ACC but still malignant.

8. Adenocarcinoma, not otherwise specified (malignant)
   A gland-type cancer that doesn’t fit other named patterns.

9. Ductal carcinoma (malignant)
   An aggressive cancer that resembles ductal cancers seen in salivary glands.

10. Lymphoma of the lacrimal gland (malignant lymphoid tumor)
    A cancer of the immune (lymphoid) cells in or around the gland. Often presents as painless swelling. Common types include MALT (marginal zone) lymphoma or diffuse large B-cell lymphoma. Work-up looks at the whole body.

Non-tumor look-alikes (important to know):

• Acute or chronic dacryoadenitis (inflammation of the gland due to infection or autoimmunity).

• IgG4-related disease (immune condition causing painless gland enlargement in many head-and-neck glands).

• Sarcoidosis (granulomatous inflammation that can enlarge the gland).
  These are not true tumors but can mimic them; doctors rule them out during evaluation.

A lacrimal gland tumor is an abnormal growth that starts in, or spreads to, the tear-producing gland. These tumors are rare (about 1 per million people per year) and make up roughly 10% of masses in the orbit (eye socket). They are grouped by:

• Epithelial vs non-epithelial (from gland cells vs from lymphoid or other tissues),

• Benign vs malignant (non-cancer vs cancer). EyeWikiWebEye

The main types

• Benign epithelial tumors

  • Pleomorphic adenoma (benign mixed tumor): the commonest benign lacrimal tumor. It’s usually slow, painless, and sits as a well-defined lump in the upper-outer orbit. Complete, careful removal is important because cutting into it or “piecemeal” removal raises the risk of recurrence and later cancer change. EyeWikiPMCJAMA NetworkOptecoto

• Malignant epithelial tumors

  • Adenoid cystic carcinoma (ACC): the commonest malignant lacrimal tumor. It tends to grow along nerves (perineural spread), can hurt, and can invade bone; local recurrence and distant spread are common over time. EyeWikiScienceDirect

  • Carcinoma ex pleomorphic adenoma, adenocarcinoma, mucoepidermoid carcinoma, salivary-duct–like carcinoma (rarer but important). JAMA NetworkNCBI

• Non-epithelial tumors

  • Lymphoma (often MALT type): a cancer of immune cells in the lacrimal gland region; it behaves very differently and is usually treated with radiotherapy and/or rituximab-based therapy. PMC+1

---

Causes and risk factors

Key point: For many lacrimal gland tumors, the exact cause is unknown. Doctors therefore list risk factors and associations—things that raise the chance or are often seen together with these tumors. I’ll mark the strength of evidence in plain language.

1. Random DNA changes during cell division (very common explanation)
   Cells sometimes make copying errors. Most are harmless; a few push cells to grow into a tumor.

2. Age (moderate evidence)
   Risks rise with age because DNA damage accumulates over time. Many malignant cases occur in middle-aged to older adults.

3. Long-standing pleomorphic adenoma (clear association)
   A benign pleomorphic adenoma can, over many years, transform into cancer (carcinoma ex pleomorphic adenoma), especially if it recurs.

4. Capsule rupture at surgery (clear association for recurrence)
   If a pleomorphic adenoma’s capsule is broken during removal, tumor cells can seed nearby tissue, causing recurrence and raising later malignant risk.

5. Specific gene rearrangements in benign tumors (research-based)
   PLAG1 or HMGA2 changes are often found in pleomorphic adenoma. These are biologic fingerprints, not things you “catch,” but they explain how the tumor arose.

6. Specific gene fusions in adenoid cystic carcinoma (research-based)
   MYB–NFIB fusion is often seen in ACC. Again, this explains biology rather than being a lifestyle cause.

7. Prior radiation exposure to head/neck (general cancer risk)
   Ionizing radiation can damage DNA. Past radiation therapy or high-dose exposure is a risk factor for many head-and-neck tumors.

8. Immune system dysregulation (moderate evidence for lymphoma)
   Conditions that weaken or confuse the immune system (e.g., HIV, post-transplant medications) can raise the risk of lymphoma, including around the lacrimal gland.

9. Autoimmune diseases (notably Sjögren’s) (moderate evidence for lymphoma)
   Ongoing immune stimulation can encourage lymphoid growths, including MALT lymphoma in ocular adnexa.

10. IgG4-related disease (association with mass-like enlargement)
    IgG4 disease mimics tumors and may coexist with lymphoid proliferation. It’s an important look-alike that prompts testing.

11. Chlamydia psittaci in ocular adnexal regions (geographic variability)
    In some regions, C. psittaci infection correlates with ocular adnexal MALT lymphoma. Not universal, but worth knowing.

12. Epstein–Barr virus (EBV) (selected lymphomas)
    EBV is linked to some lymphomas. It’s not a common direct cause of lacrimal gland tumors but enters the differential.

13. Family history of salivary-type tumors (rare but possible)
    The lacrimal gland shares biology with salivary glands. Rare familial patterns exist but are uncommon.

14. Occupational exposures (low-to-uncertain evidence)
    Some salivary-type tumors have been studied in relation to solvents, dusts, or metals. Data for the lacrimal gland itself are limited, so this is uncertain.

15. Smoking (weak/uncertain for lacrimal gland)
    Smoking drives many cancers. Its link to these specific tumors is not strong, but it’s never helpful.

16. Metastatic spread to the lacrimal region (less common cause of a mass)
    Cancers from breast, lung, or melanoma can rarely spread to the lacrimal area and appear as a “new tumor” there.

17. Chronic allergic or inflammatory eye disease (indirect, for lymphoma)
    Long-term antigenic stimulation can encourage lymphoid tissue growth, which in rare cases becomes lymphoma.

18. General cancer-predisposition syndromes (rare)
    Syndromes such as Li-Fraumeni raise overall cancer risk. Specific links to lacrimal gland tumors are rare but possible.

19. Sex (inconsistent patterns)
    Some series suggest slight differences by sex for certain subtypes, but data are mixed; consider this a minor factor.

20. Aging-related tissue microenvironment changes (supportive concept)
    Older tissues have more low-grade inflammation and less repair capacity, which can favor tumor formation in general.

Bottom line: Most patients did nothing “wrong.” In many cases, a tumor forms because of chance DNA changes and biologic quirks of lacrimal gland cells.

Symptoms and signs

1. Painless swelling at the outer upper eyelid
   “There’s a lump where the eyebrow begins.” Classic for a benign tumor.

2. A firm, smooth mass you can feel
   Often felt through the lid in the superotemporal (outer-upper) orbit.

3. Eye pushed down and inward (proptosis with displacement)
   The growing mass nudges the eye down and toward the nose.

4. Eyelid shape change or droop (“S-shaped ptosis”)
   A heavy, sagging contour over the mass.

5. Pain or deep ache
   More concerning for malignant tumors (e.g., ACC) or active inflammation.

6. Double vision (diplopia)
   The mass can limit eye movement or shift eye alignment.

7. Restricted eye movements
   Especially limited abduction (moving the eye outward) if the mass is big.

8. Blurry or reduced vision
   From pressure on the eye, dry eye, or nerve involvement.

9. Dry eye or watery eye
   Tear production may be disturbed—some people feel dryness, others watering.

10. Headache or temple discomfort
    Pressure effects or nerve irritation.

11. Numbness of forehead/eyelid
    Involvement of trigeminal nerve branches can cause altered sensation—worrisome for malignancy.

12. Redness or warmth over the gland
    Suggests inflammation more than a tumor, but tumors can inflame nearby tissues.

13. Palpable lymph nodes in front of the ear or neck
    Enlarged nodes may indicate lymphoma or spread of a carcinoma.

14. Rapid growth over weeks to a few months
    A red flag for cancer or aggressive inflammation.

15. A relative afferent pupillary defect (doctor-detected)
    A subtle pupil finding hinting at optic nerve stress when the mass is large or invasive.

---

Diagnostic tests

A) Physical exam

1. Visual acuity
   A basic letter chart test to check how clearly each eye sees. Worsening vision can signal pressure or nerve effects.

2. Inspection and palpation of the superotemporal orbit
   The doctor looks and gently feels for a firm, discrete mass, skin warmth, or tenderness. Painless, firm, well-defined masses suggest benign tumors; tender or fixed masses raise concern.

3. Exophthalmometry (Hertel)
   A small instrument measures how far the eye protrudes. Asymmetry or progression over time supports a space-occupying lesion.

4. Extraocular motility testing
   You follow a target in different directions. Restricted movement points to mechanical limitation from a mass.

B) Manual tests (office maneuvers)

5. Bimanual retropulsion test
   The doctor gently pushes the eye backward to assess orbital resistance. A stiff orbit suggests a solid lesion.

6. Upper eyelid eversion to view the palpebral lobe
   Flipping the upper lid can reveal bulging tissue from the palpebral (front) part of the gland.

7. Lacrimal gland massage/expressibility
   Gentle pressure over the gland checks for tenderness and expressions of secretion; pain points toward inflammation.

8. Regional lymph node palpation
   Feeling the preauricular (in front of ear) and neck nodes helps detect lymphoma or spread.

C) Lab and pathological tests

9. Complete blood count (CBC)
   Looks for anemia, elevated white cells, or clues to systemic lymphoma. Often normal in localized epithelial tumors.

10. Inflammation markers (ESR, CRP)
    Elevated values support inflammation; normal values do not rule out a tumor.

11. Serum IgG4 level
    If IgG4-related disease is suspected (painless gland enlargement in multiple sites), this blood test helps.

12. Viral testing when lymphoma suspected (e.g., HIV, EBV)
    Guides staging and treatment decisions for lymphoid tumors.

13. Fine-needle aspiration biopsy (FNAB) — used selectively
    A thin needle samples cells. Important caution: for a classic pleomorphic adenoma, many surgeons prefer no pre-op needle biopsy because disturbing the capsule can cause recurrence. For suspected lymphoma or carcinoma, FNAB or a core can be very helpful.

14. Incisional or excisional biopsy with histopathology
    Tissue is examined under a microscope. Immunohistochemistry (special stains) helps label cell types (e.g., CD20 for B-cells, cytokeratins for epithelial tumors). Flow cytometry can prove clonality in lymphoma. Molecular tests (e.g., MYB–NFIB, PLAG1/HMGA2) further classify tumors.

D) Electrodiagnostic tests

15. Visual evoked potential (VEP)
    Measures the brain’s response to visual signals. If a mass stresses the optic nerve, VEP can show delayed or reduced signals.

16. Electroretinogram (ERG)
    Records the retina’s electrical activity. Helpful if vision is reduced and the doctor wants to separate retinal from optic nerve/orbital causes.

E) Imaging tests

17. CT scan of the orbits with contrast
    Fast, excellent for bone detail. It can show lacrimal fossa remodeling (benign tumors) versus bone erosion (malignancy), calcifications, and lesion shape.

18. MRI of the orbits with contrast
    Best for soft tissue, nerves, and perineural spread (especially in ACC). It shows whether the mass is well-circumscribed or infiltrative, and how it relates to muscles and the optic nerve.

19. Diffusion-weighted MRI (DWI)
    Assesses water motion in tissues. Restricted diffusion can suggest higher cellularity (often seen in malignancies and lymphoma).

20. PET-CT (staging tool)
    Detects metabolically active disease throughout the body. Useful for lymphoma staging and in selected carcinomas to look for spread.

Treatment

• Benign pleomorphic adenoma: planned complete excision with an intact capsule via a lateral orbitotomy. Avoid “shelling out” or piecemeal removal and avoid unplanned biopsy that violates the capsule; both raise recurrence/malignant transformation risk. EyeWikiPMCOptecoto

• Malignant epithelial tumors (especially ACC): eye-sparing tumor resection when feasible plus adjuvant radiotherapy (including proton therapy when available). Historically, some centers used exenteration for advanced disease; modern series show good local control with orbit-sparing surgery + high-dose radiotherapy in selected cases. Intra-arterial cytoreductive chemotherapy (IACC) before surgery is being studied and may improve disease-specific survival in high-risk ACC cohorts. PMC+2PMC+2Red JournalPubMedOxford Academic

• Lacrimal gland lymphoma (MALT and similar): radiotherapy (typically ~20–30 Gy in fractions) achieves excellent local control; rituximab-based systemic therapy is used in selected or disseminated cases. PMC+1ScienceDirect

---

Non-pharmacological treatments

These support comfort, eye surface health, rehabilitation, or reduce treatment side-effects. They do not shrink tumors (surgery/radiation/oncology drugs do that).

1. Observation with short-interval imaging only in carefully selected, indeterminate cases where imaging and exam suggest low risk; otherwise benign pleomorphic adenoma is removed, not watched. Purpose: safety when diagnosis uncertain. Mechanism: early detection of change. EyeWiki

2. Lateral orbitotomy with intact-capsule excision (benign PA) — strictly surgical technique but listed here for its non-drug nature. Purpose: cure. Mechanism: removes tumor en bloc, prevents seeding. Optecoto

3. Orbit-sparing resection for malignancy (selected cases). Purpose: cancer control plus vision preservation. Mechanism: negative margins where possible. PMC

4. Radiotherapy (photons or protons) after surgery. Purpose: lower recurrence. Mechanism: DNA damage to residual cancer cells. PMC+1

5. Proton beam radiotherapy when available. Purpose: focus dose, spare brain/optic pathways. Mechanism: Bragg peak energy deposition. PMC

6. Custom immobilization and eye shielding during RT. Purpose: protect sensitive structures. Mechanism: precise dose delivery. Red Journal

7. Preservative-free artificial tears and gels during/after RT. Purpose: treat dry eye from lacrimal damage. Mechanism: tear film replacement.

8. Moisture-chamber goggles / humidifiers. Purpose: reduce evaporation. Mechanism: create a humid micro-environment.

9. Temporary or permanent punctal occlusion for severe dryness post-RT. Purpose: retain tears. Mechanism: block drainage.

10. Scleral contact lenses for exposure-related dryness. Purpose: protect cornea. Mechanism: fluid reservoir over the cornea.

11. Prism glasses or patching for diplopia. Purpose: relieve double vision. Mechanism: redirect images or occlude one eye.

12. Eyelid taping at night if incomplete closure. Purpose: corneal protection.

13. Scar care after surgery (silicone gel, gentle massage once cleared). Purpose: smoother eyelid contour.

14. Oculoplastic prosthesis after exenteration (orbital prosthetic/epithesis). Purpose: facial rehabilitation and confidence. Mechanism: custom silicone device.

15. Low-vision aids if vision is reduced. Purpose: function and reading.

16. Smoking cessation and alcohol moderation. Purpose: better wound and tissue healing; overall cancer outcomes.

17. Nutrition counseling with adequate protein (often 1.2–1.5 g/kg/day during treatment). Purpose: maintain lean mass and healing. Mechanism: supports anabolism. PMC+1

18. Psychological support and support groups. Purpose: coping with cancer treatment and body-image changes.

19. Physical therapy (posture/neck/shoulder) after orbital surgery or radiation. Purpose: reduce tension headaches, improve function.

20. Regular dental/ocular surface care during RT. Purpose: reduce infection and keratopathy risk.

---

Drug treatments

Doses below are typical starting points from head-and-neck/salivary-type protocols. Final dosing is individualized by your oncology team.

1. Cyclophosphamide (alkylator), usually part of CAP. Dose example: 500 mg/m² IV day 1 q21–28 days (with doxorubicin + cisplatin). Purpose: palliative control in advanced salivary-type cancers incl. ACC. Mechanism: DNA crosslinks. Side-effects: low blood counts, nausea, cystitis. Cancer Care Ontario

2. Doxorubicin (anthracycline), in CAP. Dose example: 50 mg/m² IV day 1 q21–28 days. Purpose: as above. Mechanism: DNA intercalation/topo-II inhibition. Side-effects: fatigue, hair loss, cardiotoxicity (dose-limited). Cancer Care Ontario

3. Cisplatin (platinum), in CAP or with RT. Dose examples: 50 mg/m² day 1 q3–4 weeks in CAP; or 100 mg/m² every 3 weeks × 3 cycles with radiation in head-and-neck paradigms. Purpose: radiosensitizer/chemo for aggressive disease. Side-effects: kidney injury, hearing loss, neuropathy, nausea (needs strong antiemetics). Cancer Care OntarioASCO Publications

4. Carboplatin (platinum) + Paclitaxel (taxane). Dose examples: paclitaxel 100–200 mg/m² + carboplatin AUC 5–6 q3 weeks. Purpose: alternative doublet used for recurrent/metastatic salivary-type cancers; modest responses. Side-effects: neuropathy, low counts, fatigue. PMC+1Karger

5. 5-Fluorouracil (antimetabolite). Dose: often continuous infusion when paired with platinum in head-and-neck regimens. Purpose: palliative chemo in selected cases. Side-effects: mucositis, hand–foot syndrome. ASCO Publications

6. Vinorelbine (vinca). Dose: 25–30 mg/m² IV weekly or q2w, sometimes with cisplatin. Purpose: salivary-type cancers; some responses. Side-effects: neutropenia, neuropathy. PMC

7. Lenvatinib (VEGFR/FGFR TKI). Dose: 20–24 mg orally daily (adjust as needed). Purpose: disease control in recurrent/metastatic ACC—objective responses and frequent disease stabilization in trials; toxicities require close monitoring. Side-effects: hypertension, proteinuria, fatigue, diarrhea, hand–foot reaction. PMC+1ACS Publications

8. Axitinib (VEGFR TKI). Dose: 5 mg orally twice daily. Purpose: studied vs observation in R/M ACC; disease stabilization reported. Side-effects: hypertension, diarrhea, fatigue. ASCO

9. Pembrolizumab (PD-1 inhibitor). Dose: 200 mg IV q3 weeks or 400 mg q6 weeks. Purpose: immunotherapy tried in R/M ACC; objective responses are uncommon, but some patients achieve stable disease or benefit when combined with RT in trials. Side-effects: immune-related (thyroid, liver, lung, skin). PMCMDPI

10. Rituximab (anti-CD20 antibody) for lacrimal gland lymphomas. Dose: 375 mg/m² IV weekly × 4 (varies) ± chemotherapy (e.g., R-CHOP), or with involved-site radiotherapy for localized disease. Side-effects: infusion reactions, infection risk, HBV reactivation (screening needed). PMCDove Medical Press

Important: Many “targeted” and immune drugs for ACC are off-label and used in trials or specialized centers. Discuss eligibility for clinical trials.

---

Dietary / molecular & other supportive supplements

None of these treat the tumor. They aim to reduce side-effects, support nutrition, or help you stay strong during therapy. Always clear supplements with your oncology team to avoid interactions.

1. Protein supplementation (whey or medical ONS) to reach ~1.2–1.5 g/kg/day during treatment. Function: preserve muscle; Mechanism: supplies essential amino acids. PMC

2. High-protein oral nutrition shakes when appetite is low. Mechanism: convenient protein/energy. PMC

3. Omega-3 fatty acids (EPA/DHA) 1–2 g/day under supervision. Function: may help weight maintenance in cancer cachexia; Mechanism: anti-inflammatory lipid mediators. PubMed+1

4. Ginger (e.g., standardized capsules totalling ~0.5–1 g/day) during chemo days. Function: nausea relief; Mechanism: 5-HT₃ modulation. PMCPubMed

5. Vitamin D (per blood level; many adults need 600–800 IU/day, not exceeding 4,000 IU/day unless a clinician prescribes). Function: bone/immune health; Mechanism: nuclear receptor signaling. Office of Dietary SupplementsCancer.gov

6. Probiotics (oncology-approved strains) if you’re not neutropenic. Function: may reduce treatment-related diarrhea. Mechanism: microbiome support. PMC+1

7. Electrolyte solutions (oral rehydration) during nausea/diarrhea days. Function: maintain hydration/salts.

8. Soluble fiber (oats/psyllium) for bowel regularity, if not neutropenic or severely immunosuppressed.

9. Thick eye gels/ointments at night (not a “dietary” item, but crucial supportive). Function: protect cornea during dryness.

10. Selenium, zinc only if a documented deficiency—do not megadose.

11. B-complex if intake is poor or on medications that deplete B vitamins; avoid megadoses.

12. Calcium only if dietary intake is low and vitamin D is corrected.

13. Magnesium if low, especially with platinum chemotherapy (which can waste Mg).

14. Simple smoothies (fruit/veg + yogurt/nut butter) to add calories and protein gently.

15. Avoid antioxidant megadoses during radiation/chemo unless your team approves (they might blunt treatment-related oxidative damage to tumor cells).

---

Regenerative / stem-cell–type” drugs

There are no approved stem-cell drugs to treat lacrimal gland tumors. Clinics advertising “stem cell cures” for eye cancers are not evidence-based. What is used or studied are immune and targeted therapies:

1. Pembrolizumab (PD-1 inhibitor) — limited responses in ACC; sometimes stabilizes disease; used in trials. PMCMDPI

2. Nivolumab (PD-1 inhibitor) — similar, limited activity; trial-based. MDPI

3. Lenvatinib (VEGFR/FGFR inhibitor) — oral targeted drug with measurable activity in R/M ACC. PMC

4. Axitinib (VEGFR inhibitor) — disease stabilization in some R/M ACC patients. ASCO

5. Sorafenib/Sunitinib (VEGFR multikinase inhibitors) — used in small series; generally stabilize rather than shrink ACC. ScienceDirect

6. Rituximab (CD20 antibody) — effective immune therapy for lymphomas of the lacrimal gland region. PMC

Experimental combos (e.g., STING agonists + PD-1 blockers) are being explored; ask about clinical trials at tertiary centers. jitc.bmj.com

---

Surgeries

1. Lateral orbitotomy with intact-capsule excision (pleomorphic adenoma): a careful side-of-orbit approach; the whole tumor is lifted out without cutting it. Why: best chance of cure, minimizes recurrence. EyeWiki

2. Orbit-sparing tumor resection (malignancy): remove tumor with safe margins, preserving the eye when possible. Why: maintain vision while controlling local disease. PMC

3. Exenteration (remove eye and orbital contents) for very advanced, recurrent, or invasive cancers. Why: life-saving local control when other options can’t clear disease. PMC

4. Bone reconstruction (if tumor removes bone) and lid repairs to restore form and function. Why: protect the eye, improve symmetry.

5. Biopsy with planned track excision (when diagnosis is uncertain or lymphoma suspected). Why: obtain tissue safely and avoid seeding. Optecoto

---

Prevention pointers

We cannot fully prevent these rare tumors, but we can lower risks of complications and recurrence:

1. Don’t biopsy a classic pleomorphic adenoma unless necessary; refer to an oculoplastic oncologist. EyeWiki

2. Choose experienced surgical centers to maximize intact removal and proper margins. Optecoto

3. Complete adjuvant radiotherapy when recommended (ACC). PMC

4. Attend scheduled imaging follow-up (ACC can recur years later). Cell

5. Protect the ocular surface during/after RT (tears, shields). Red Journal

6. Vaccinate and screen (e.g., HBV before rituximab). Dove Medical Press

7. Stop smoking, limit alcohol (general oncologic benefit).

8. Maintain nutrition/protein intake during treatment. PMC

9. UV and injury protection around the treated eye.

10. Manage comorbidities (blood pressure, diabetes) to tolerate therapy better.

---

When to see a doctor (red flags)

• A new, firm lump in the outer upper eyelid/orbit.

• Eye pain, rapid growth, or numbness in forehead/cheek.

• Double vision, new droopy lid, or vision loss.

• Any mass with bone changes on imaging.

• If you had a pleomorphic adenoma removed and you notice any new fullness years later (recurrence can be multifocal). PMC

---

What to eat and what to avoid

Eat more of:

• Protein-rich foods (eggs, fish, chicken, dal, tofu, yogurt, nuts) at every meal; aim for ~1.2–1.5 g/kg/day total protein with help from shakes if needed. PMC

• Colorful fruits/vegetables for fiber and micronutrients.

• Whole grains and healthy fats (olive oil, nuts, seeds).

• Plenty of fluids (water, oral rehydration solutions during sick days).

Limit/avoid:

• Raw or undercooked animal foods when neutropenic or on intense chemo.

• Unwashed produce and street foods if your counts are low.

• Alcohol (interacts with many meds; dehydrates).

• High-dose antioxidant supplements during RT/chemo (unless approved). Cancer.gov

---

FAQs

1) Are lacrimal gland tumors common?
No: about 1 per million per year. EyeWiki

2) What’s the most common benign type?
Pleomorphic adenoma. It’s usually painless and slow. EyeWiki

3) What’s the most common malignant type?
Adenoid cystic carcinoma (ACC). American Journal of Roentgenology

4) Do benign tumors need to be removed?
Yes—pleomorphic adenomas are removed intact to prevent recurrence or malignant change. EyeWiki

5) Is biopsy always done first?
Not if imaging strongly suggests pleomorphic adenoma—biopsy that breaks the capsule can seed cells. For suspected malignancy or lymphoma, a planned biopsy is done. Optecoto

6) What is the standard for ACC?
Orbit-sparing surgery when feasible plus adjuvant high-dose radiotherapy (including protons where available). PMC+1

7) What is IACC?
Neoadjuvant intra-arterial cytoreductive chemotherapy—catheter-delivered chemo to shrink ACC before surgery; emerging data suggest survival benefit in high-risk groups, but it’s specialized. PubMed+1

8) Do immunotherapies work for ACC?
They’ve shown limited objective responses so far; some patients get stable disease. Trials continue. PMCMDPI

9) What about targeted pills like lenvatinib?
They can slow or shrink some ACCs but need close monitoring for side-effects. PMC

10) How are lacrimal lymphomas treated?
Often with involved-site radiotherapy (excellent control) and sometimes rituximab-based therapy. PMC+1

11) What is exenteration and why is it done?
Removal of eye and orbital tissues for very advanced or recurrent cancers when other options can’t control it. PMC

12) Can these tumors come back?
Yes—especially ACC (even years later) and pleomorphic adenoma if the capsule was violated. Lifelong follow-up is common. CellPMC

13) Will treatment affect my tears or vision?
Possibly. Surgery/RT can cause dry eye or blur; tear care and protective strategies help. Red Journal

14) Should I take supplements?
Only what your team approves. Prioritize protein, hydration, and balanced meals; avoid megadoses that could interact with care. PMC

15) Where should I be treated?
At a center with oculoplastic oncology and head-and-neck/skull-base experience; ask about clinical trials.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 10, 2025.

PDF Document For This Disease Conditions References